107 related articles for article (PubMed ID: 36594508)
1. Endogenous G-quadruplex-forming RNAs inhibit the activity of SARS-CoV-2 RNA polymerase.
Endoh T; Takahashi S; Sugimoto N
Chem Commun (Camb); 2023 Jan; 59(7):872-875. PubMed ID: 36594508
[TBL] [Abstract][Full Text] [Related]
2. ATP enhances the error-prone ribonucleotide incorporation by the SARS-CoV-2 RNA polymerase.
Pourfarjam Y; Ma Z; Kim IK
Biochem Biophys Res Commun; 2022 Oct; 625():53-59. PubMed ID: 35947915
[TBL] [Abstract][Full Text] [Related]
3. Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.
Bai X; Sun H; Wu S; Li Y; Wang L; Hong B
Front Immunol; 2022; 13():844749. PubMed ID: 35464436
[TBL] [Abstract][Full Text] [Related]
4. Identification of G-quadruplex DNA sequences in SARS-CoV2.
Maiti AK
Immunogenetics; 2022 Oct; 74(5):455-463. PubMed ID: 35303126
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
[TBL] [Abstract][Full Text] [Related]
6. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
7. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
8. Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders.
Moraca F; Marzano S; D'Amico F; Lupia A; Di Fonzo S; Vertecchi E; Salvati E; Di Porzio A; Catalanotti B; Randazzo A; Pagano B; Amato J
Chem Commun (Camb); 2022 Oct; 58(85):11913-11916. PubMed ID: 36196950
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of RNA G-quadruplexes in the SARS-CoV-2 genome inhibits viral infection via translational suppression.
Razzaq M; Han JH; Ravichandran S; Kim J; Bae JY; Park MS; Kannappan S; Chung WC; Ahn JH; Song MJ; Kim KK
Arch Pharm Res; 2023 Jul; 46(7):598-615. PubMed ID: 37563335
[TBL] [Abstract][Full Text] [Related]
10. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
Wang X; Sacramento CQ; Jockusch S; Chaves OA; Tao C; Fintelman-Rodrigues N; Chien M; Temerozo JR; Li X; Kumar S; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Bozza PT; Russo JJ; Souza TML; Ju J
Commun Biol; 2022 Feb; 5(1):154. PubMed ID: 35194144
[TBL] [Abstract][Full Text] [Related]
11. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
[TBL] [Abstract][Full Text] [Related]
12. Targeting RNA G-Quadruplex in SARS-CoV-2: A Promising Therapeutic Target for COVID-19?
Zhao C; Qin G; Niu J; Wang Z; Wang C; Ren J; Qu X
Angew Chem Int Ed Engl; 2021 Jan; 60(1):432-438. PubMed ID: 32939952
[TBL] [Abstract][Full Text] [Related]
13. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target.
Wang Y; Anirudhan V; Du R; Cui Q; Rong L
J Med Virol; 2021 Jan; 93(1):300-310. PubMed ID: 32633831
[TBL] [Abstract][Full Text] [Related]
14. Effects of natural RNA modifications on the activity of SARS-CoV-2 RNA-dependent RNA polymerase.
Petushkov I; Esyunina D; Kulbachinskiy A
FEBS J; 2023 Jan; 290(1):80-92. PubMed ID: 35916766
[TBL] [Abstract][Full Text] [Related]
15. Structure and Dynamics of RNA Guanine Quadruplexes in SARS-CoV-2 Genome. Original Strategies against Emerging Viruses.
Miclot T; Hognon C; Bignon E; Terenzi A; Marazzi M; Barone G; Monari A
J Phys Chem Lett; 2021 Oct; 12(42):10277-10283. PubMed ID: 34652910
[TBL] [Abstract][Full Text] [Related]
16. Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
Bennett RP; Yoluç Y; Salter JD; Ripp A; Jessen HJ; Kaiser SM; Smith HC
Antiviral Res; 2023 Oct; 218():105716. PubMed ID: 37690700
[TBL] [Abstract][Full Text] [Related]
17. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Jockusch S; Tao C; Li X; Anderson TK; Chien M; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
Antiviral Res; 2020 Aug; 180():104857. PubMed ID: 32562705
[TBL] [Abstract][Full Text] [Related]
18. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus genomic cDNA derived G-quadruplex as a selective target for fluorometric detection.
Pratihar S; Mattath MN; Govindaraju T
Chem Commun (Camb); 2023 May; 59(38):5717-5720. PubMed ID: 37092254
[TBL] [Abstract][Full Text] [Related]
20. Unusual topological RNA G-quadruplex formed by an RNA duplex: implications for the dimerization of SARS-CoV-2 RNA.
Wang S; Song Y; He Z; Saneyoshi H; Iwakiri R; Xu P; Zhao C; Qu X; Xu Y
Chem Commun (Camb); 2023 Oct; 59(85):12703-12706. PubMed ID: 37819218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
